RU2488384C2 - Композиции для лечения неопластических заболеваний - Google Patents
Композиции для лечения неопластических заболеваний Download PDFInfo
- Publication number
- RU2488384C2 RU2488384C2 RU2010110658/15A RU2010110658A RU2488384C2 RU 2488384 C2 RU2488384 C2 RU 2488384C2 RU 2010110658/15 A RU2010110658/15 A RU 2010110658/15A RU 2010110658 A RU2010110658 A RU 2010110658A RU 2488384 C2 RU2488384 C2 RU 2488384C2
- Authority
- RU
- Russia
- Prior art keywords
- composition according
- taxane
- weight
- carrier
- pvp
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 18
- 201000010099 disease Diseases 0.000 title claims abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract 3
- 230000001613 neoplastic effect Effects 0.000 title claims abstract 3
- 229940123237 Taxane Drugs 0.000 claims abstract 17
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims abstract 17
- 239000004094 surface-active agent Substances 0.000 claims abstract 6
- 238000000034 method Methods 0.000 claims abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims abstract 3
- 239000007787 solid Substances 0.000 claims abstract 3
- 239000012052 hydrophilic carrier Substances 0.000 claims abstract 2
- 239000007962 solid dispersion Substances 0.000 claims abstract 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 5
- 238000004108 freeze drying Methods 0.000 claims 4
- 229920000858 Cyclodextrin Polymers 0.000 claims 2
- 208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 claims 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 2
- -1 carboxymethyl ethyl Chemical group 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229920003080 Povidone K 25 Polymers 0.000 claims 1
- 229920003081 Povidone K 30 Polymers 0.000 claims 1
- 229920003082 Povidone K 90 Polymers 0.000 claims 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- 229940097362 cyclodextrins Drugs 0.000 claims 1
- 239000008121 dextrose Substances 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 229960004667 ethyl cellulose Drugs 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 229920001477 hydrophilic polymer Polymers 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 229940100691 oral capsule Drugs 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920000193 polymethacrylate Polymers 0.000 claims 1
- 229920005862 polyol Polymers 0.000 claims 1
- 150000003077 polyols Chemical class 0.000 claims 1
- 229920002689 polyvinyl acetate Polymers 0.000 claims 1
- 239000011118 polyvinyl acetate Substances 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical group N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 1
- 229960000311 ritonavir Drugs 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 238000000935 solvent evaporation Methods 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95776407P | 2007-08-24 | 2007-08-24 | |
| GB0716591.3 | 2007-08-24 | ||
| US60/957,764 | 2007-08-24 | ||
| GB0716591A GB0716591D0 (en) | 2007-08-24 | 2007-08-24 | Composition |
| PCT/GB2008/002854 WO2009027644A2 (en) | 2007-08-24 | 2008-08-22 | Composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010110658A RU2010110658A (ru) | 2011-09-27 |
| RU2488384C2 true RU2488384C2 (ru) | 2013-07-27 |
Family
ID=38599259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010110658/15A RU2488384C2 (ru) | 2007-08-24 | 2008-08-22 | Композиции для лечения неопластических заболеваний |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP5404625B2 (OSRAM) |
| CN (1) | CN101854919B (OSRAM) |
| ES (1) | ES2535401T3 (OSRAM) |
| GB (1) | GB0716591D0 (OSRAM) |
| RU (1) | RU2488384C2 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR086913A1 (es) * | 2011-06-14 | 2014-01-29 | Novartis Ag | 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas |
| WO2015152433A1 (en) | 2014-03-31 | 2015-10-08 | Hanmi Pharm. Co., Ltd. | Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same |
| CN105106420A (zh) * | 2015-07-30 | 2015-12-02 | 马衍福 | 一种抗肿瘤疾病中药制剂 |
| EP3595633B1 (en) | 2017-03-15 | 2023-07-05 | DFB Soria, LLC | Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes |
| CN111465389B (zh) | 2017-09-07 | 2022-06-21 | 深圳信立泰药业股份有限公司 | 多西他赛共缀物的药物组合物及制备方法 |
| KR20220002860A (ko) * | 2018-12-21 | 2022-01-07 | 모드라 파마슈티컬스 비.브이. | 피크 혈장 수준의 제어에 의한 도세탁셀을 사용하는 암 치료 |
| US20220071944A1 (en) * | 2018-12-21 | 2022-03-10 | Modra Pharmaceuticals B.V. | Combination Treatment for Solid Tumors Using Docetaxel and a CYP3A Inhibitor |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004012714A1 (en) * | 2002-08-05 | 2004-02-12 | Dsm Ip Assets B.V. | Oral dosage forms of water insoluble drugs and methods of making the same |
| WO2004050058A2 (en) * | 2002-11-29 | 2004-06-17 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL146659A0 (en) * | 1999-05-27 | 2002-07-25 | Acusphere Inc | Porous drug matrices and method of manufacture thereof |
| KR100508518B1 (ko) * | 2002-11-13 | 2005-08-17 | 한미약품 주식회사 | 초임계유체 공정을 이용한 파클리탁셀 고체분산체의 제조방법 및 이 방법으로 제조된 파클리탁셀 고체분산체 |
-
2007
- 2007-08-24 GB GB0716591A patent/GB0716591D0/en not_active Ceased
-
2008
- 2008-08-22 RU RU2010110658/15A patent/RU2488384C2/ru active
- 2008-08-22 JP JP2010521478A patent/JP5404625B2/ja active Active
- 2008-08-22 ES ES08788414.4T patent/ES2535401T3/es active Active
- 2008-08-22 CN CN2008801042752A patent/CN101854919B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004012714A1 (en) * | 2002-08-05 | 2004-02-12 | Dsm Ip Assets B.V. | Oral dosage forms of water insoluble drugs and methods of making the same |
| WO2004050058A2 (en) * | 2002-11-29 | 2004-06-17 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
Non-Patent Citations (1)
| Title |
|---|
| IKEZOE T. «HIV-1 protease inhibitor, ritonavir: A potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo» // Cancer Research, 2004, p.7426-74316164 [онлайн]. [Найдено в Интернет 03.05.2012] <URL:http://www.ncbi.nlm.nih.gov/pubmed/15492266>. BARDELMEIJER H.A. «Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted be rotonavir» // Cancer Research, 2002, p.6158-6164 [онлайн]. [Найдено в Интернет 03.05.2012] <URL:http://www.ncbi.nlm.nih.gov/pubmed/12414642 >. * |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2010110658A (ru) | 2011-09-27 |
| GB0716591D0 (en) | 2007-10-03 |
| BRPI0816144A2 (pt) | 2015-02-18 |
| ES2535401T3 (es) | 2015-05-11 |
| JP2010536837A (ja) | 2010-12-02 |
| CN101854919B (zh) | 2012-02-15 |
| CN101854919A (zh) | 2010-10-06 |
| JP5404625B2 (ja) | 2014-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2488384C2 (ru) | Композиции для лечения неопластических заболеваний | |
| Luo et al. | Multifunctional role of polyvinylpyrrolidone in pharmaceutical formulations | |
| ES2399810T3 (es) | Forma de dosificación farmacéutica sólida que comprende una dispersión sólida de ritonavir y lopinavir | |
| ES2409055T3 (es) | Sistema de suministro de fármacos que comprende polioxazolina y un agente bioactivo | |
| US10632074B2 (en) | Composite granulated product including sugar or sugar alcohol, swelling binder, disintegrating agent and highly absorbent excipient, and method for manufacturing composite granulated product | |
| EP3076951B1 (en) | Process for the production of drug formulations for oral administration | |
| US8603539B2 (en) | Compositions for drug delivery | |
| RU2435592C2 (ru) | Композиция пролекарства для борьбы с вирусом гепатита с | |
| ES2894112T3 (es) | Nanopartículas que contienen tacrolimus | |
| CA2976811A1 (en) | Solid dispersions of ospemifene | |
| RU2018109496A (ru) | Фармацевтическая композиция, содержащая электрогидродинамически полученные волокна, композиция, имеющая улучшенное время удержания в месте применения | |
| CN104352482A (zh) | 膜组合物 | |
| Kumari et al. | Paramount role of solid dispersion in enhancement of solubility | |
| WO2015030854A1 (en) | Solid dispersion formulation of an antiviral compound | |
| JP2019519570A5 (OSRAM) | ||
| JP2010536837A5 (OSRAM) | ||
| JP2019524724A (ja) | テコビリマットの経口用医薬組成物及びその調製法 | |
| RU2342926C2 (ru) | Способ получения низкокристаллического олтипраза или аморфного олтипраза | |
| CN101868232B (zh) | 包含紫杉烷衍生物的具有改进的重构时间的冻干药物组合物及其制备方法 | |
| WO2017155020A1 (ja) | 微細粒子含有組成物およびその製法 | |
| US9284341B2 (en) | Rapidly dissolving pharmaceutical composition | |
| JP6666352B2 (ja) | デュタステリド含有固体分散体及びこれを含む組成物 | |
| CN101827584A (zh) | N-芳基脲基药物的固态分散体产品 | |
| JP2012500788A5 (OSRAM) | ||
| CA2878689A1 (en) | Crystalline forms of an hcv inhibitor |